New Strong Sell Stocks for February 26th
BXMT, BMY and CWEN have been added to the Zacks Rank #5 (Strong Sell) List on February 26, 2023.
Bristol Myers' (BMY) Krazati sNDA for CRC Gets Priority Review
Bristol Myers (BMY) announces FDA's acceptance of the sNDA seeking approval for the Krazati/Erbitux combo therapy to treat CRC patients. A final decision is expected on Jun 21, 2024.
Should You Pick Bristol Myers Squibb Stock After A 30% Fall Last Year And Q4 Beat?
Bristol Myers Squibb BMY (NYSE: BMY) reported its Q4 results earlier this month, with revenues and earnings beating the street estimates. The company reported revenue of $11.5 billion and adjusted ...
The 3 Best Stocks Beginning Investors Can Buy: February 2024
Picking the best stocks for beginning investors is crucial as they enter the world of long-term investing. With a myriad of options available, it's essential to focus on stocks that offer growth po...
A Look at Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs...
J&J, Merck and Bristol Myers CEOs, under fire on Capitol Hill, seek to turn up heat on drug-market middlemen
Drugmakers grilled on the cost of prescription drugs on Capitol Hill Thursday sought to deflect the criticism onto drug-market middlemen who they said are pushing list prices for medications higher.
US Senate Democrats grill pharma CEOs on drug prices
U.S. Senate Democrats grilled three top pharmaceutical executives over the high cost of prescription drugs on Thursday but failed to extract any commitments from them to lower prices.
Bristol Myers' (BMY) Opdivo Label Expansion Filings Get Accepted
Bristol Myers (BMY) announces the acceptance of its regulatory filings for the perioperative Opdivo regimen to treat a lung cancer indication in the United States and EU.
JAZZ Boosts Oncology Pipeline With KRAS Inhibitor Program
JAZZ inks a deal to acquire global rights to Redx Pharma's KRAS inhibitor program to strengthen its early-stage oncology pipeline.
Pharma CEOs Will Testify Today Over Prescription Drug Prices: Here's What To Watch For
Chief executives from three major pharmaceutical companies will testify before a Senate committee on Thursday, following a back-and-forth with Sen. Bernie Sanders (I-Vt.
Senators to question Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricing
The push to cut drug prices is one of those rare hot-button issues that unites the two major political parties.
Merck, J&J and Bristol Myers CEOs face drug-pricing grilling on Capitol Hill, but experts cite deeper problems under the radar
Lawmakers seeking to hold drugmakers accountable for high prescription-drug costs are focusing on some prices that shed little light on the problem, drug-pricing experts say.
Bristol Myers (BMY), TSVT CAR T-Cell Therapy to Face FDA's ODAC
Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.
Analyst: Positive Catalysts Can't Save This Pharma Stock
Biopharmaceutical stock Bristol-Myers Squibb Co (NYSE:BMY) is in focus this morning, after a downgrade to "neutral" from "buy" at Redburn-Atlantic.
Bristol Myers Squibb Shares Cross 5% Yield Mark
In trading on Monday, shares of Bristol Myers Squibb were yielding above the 5% mark based on its quarterly dividend (annualized to $2.4), with the stock changing hands as low as $47.68 on the day....
Related Companies